LU1988887292

Janus Henderson Horizon Biotechnology Fund(LU1988887292)

Equities
Global
SGD Cash, SRS
Accumulating

Invest with

SGD Cash, SRS

Payout type

Accumulating

Risk rating

About this fund

Description

The Fund aims to provide capital growth over the long term. The Fund invests at least 80% of its assets in shares (equities) and equity-related securities of companies, which are biotechnology or biotechnology-related, in any country

Key information

Annual report

View

Product Highlight Sheet

View

Prospectus

View

Factsheet

View

Our perspective

Why we think this fund is best-in-class

Product

Actively managed diversified biotechnology portfolio with 50-80 holdings across all size and stages, with a tilt towards smaller-sized developmental stage companies.

People

Stable 3-man portfolio management team led by Andy Acker, an industry veteran with 27 years of experience. All three managers have specialist knowledge in biochemistry, which is beneficial for understanding the industry and making sense of new drug launches and pipelines.The team is further supported by a dedicated biotech analyst, and the broader Janus Henderson Healthcare team.

Performance

Robust track record in delivering outperformance relative to the NASDAQ Biotechnology TR Index, and the broader MSCI World Index.The Fund is highly volatile, as witnessed by its steep drawdown in May 2022. Nonetheless, the fund rebounded stronger and quicker relative to its index. Over a three year period (as of end September 2023), the fund has registered a higher up-capture ratio than down-capture ratio, delivering positive returns.

Process

Balanced portfolio construction with diversified all-cap exposure to companies across the developmental, early commercial and profitable stages.Intensive fundamental analysis that goes beyond engaging with company management, and often involving interactions with physicians and industry experts.Robust risk management process that seeks to mitigate the downside with position sizing limited such that in the worst case scenario, estimated adverse impact from a particular event should not exceed 2% of the portfolio’s performance.

Cost

Access to the retail share class with 100% trailer fee rebated back to Endowus investors to achieve a lower cost of access.

How it fits in a portfolio

Biotech investing is highly influenced by binary events such as clinical trial success, FDA approvals, and merger and acquisition activities. This can introduce extreme volatility in stock prices.Investors who seek higher return potential from biotechnology investing and are comfortable with the elevated volatility that accompanies this asset class, may choose to consider the fund as a satellite holding within a globally diversified portfolio.As of 30/9/2023

Compare funds

Performance

Returns

NAV

Shows the total return of this accumulating fund, which includes dividends reinvested.

Total returns

Cumulative

Annualised

All Time

237.32%

YTD

-0.34%

1 month

-0.49%

6 month

29.08%

1 year

55.08%

3 year

86.44%

5 year

74.89%

As of Mar 2026

Distributions

This is an accumulating fund, so dividends are re-invested at the fund level.

Risk metrics

Max drawdown

-34.82%As of Mar 2026

Volatility

21.07%As of Mar 2026

Calendar returns

Year	Total	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026	-	-0.0%	0.2%	-0.5%	-	-	-	-	-	-	-	-	-
2025	41.1%	5.0%	-7.1%	-7.1%	1.5%	-6.6%	4.6%	8.7%	3.8%	7.3%	18.6%	9.7%	-0.5%
2024	9.2%	5.2%	6.1%	-1.8%	-3.5%	3.4%	3.6%	6.1%	-1.2%	-1.9%	2.9%	-0.6%	-8.4%
2023	21.4%	0.2%	-0.8%	0.6%	5.1%	5.3%	1.0%	-0.3%	1.9%	-2.4%	-11.8%	8.9%	14.0%
2022	-4.3%	-18.5%	-0.7%	0.3%	-7.8%	-6.0%	3.8%	4.3%	7.5%	6.5%	6.9%	1.0%	1.7%
Load more		5 of 8

Top Exposures

Holdings

Regions

Sectors

Praxis Precision Medicines Inc Ordinary Shares	6.60%
Revolution Medicines Inc Ordinary Shares	4.55%
argenx SE ADR	4.06%
BridgeBio Pharma Inc	4.01%
Vertex Pharmaceuticals Inc	3.84%
Regeneron Pharmaceuticals Inc	3.51%
AstraZeneca PLC ADR	3.50%
United Therapeutics Corp	3.15%
Gilead Sciences Inc	3.10%
Ascendis Pharma AS ADR	3.10%
Madrigal Pharmaceuticals Inc	2.99%
Mirum Pharmaceuticals Inc	2.88%
Travere Therapeutics Inc Ordinary Shares	2.81%
Amgen Inc	2.80%
PTC Therapeutics Inc	2.49%

Top exposures represent up to 15 of the fund's largest exposures for each category. Allocation percentages may not sum up to 100% and can include negative values due to rounding or trading activities by the underlying fund managers, including short positions.

Fund fees

2.95%2.23% p.a.

Save 24%

Fund facts

ISIN

LU1988887292

Fund house

Janus Henderson

Fund size

S$2.2B

As of 17 Apr 2026

Fund inception date

13 Sep 2019

Fund class currency

SGD

Fund share class

A2 SGD

Oldest share class ISIN

LU1897414642

Oldest share inception date

10 Dec 2018

Pricing frequency

Daily

Disclaimer: ©2025 Morningstar. All Rights Reserved. The information contained here relating to a particular collective investment scheme: (1) is proprietary to Morningstar Research Pte. Limited and/or its content providers (“Information Provider(s)“) unless otherwise specified; and (2) may not be copied or distributed. Neither the Information Provider nor Endowus guarantee or endorse the accuracy, reliability, completeness or timeliness of the information, or are responsible for any damages or losses arising from any use of this information. Further, for technical reasons, certain information provided by Information Provider may be different from that supplied by the respective fund houses.

This website is for information purposes only and is not and should not be construed as an offer or the solicitation of an offer or a recommendation for the purchase or sale of any investment or subscribe for, or to participate in, any services. Any opinion or estimate above is made on a general basis and none of Endowus, nor any of its affiliates, representatives, or agents have given any consideration to nor have made any investigation of the objective, financial situation, or particular need of any user, reader, any specific person or group of persons. Opinions expressed herein are subject to change without notice. You should carefully consider whether any investment views and investment products/services are appropriate in view of your investment experience, objectives, financial resources and relevant circumstances or seek financial advice via Endowus' platform.

Investment involves risk. The value of investments and the income from them can go down as well as up, and you may not get the full amount you invested. Past performance is not an indicator nor a guarantee of future performance. Rates of exchange may cause the value of investments to go up or down. Individual stock performance does not represent the return of a fund.

You are responsible for downloads from this website. Endowus does not warrant that any downloads from this website will meet your needs or expectations, or be uninterrupted, secure, or error free or that any files available for downloading through this website are free of computer viruses or other harmful components. You alone are responsible for ensuring adequate protection and backup of data, software, computer, and other equipment is made and appropriate safeguard is in place to detect, prevent and eliminate computer viruses and other harmful effects. Neither Endowus nor the Information Provider will be responsible for any costs or expenses which may be incurred if your use of this website or if any downloads results in any servicing or replacement of property, material, equipment, or data.

This advertisement has not been reviewed by the Monetary Authority of Singapore.